In this issue of Cell Chemical Biology, Palve et al. (2022) identified PARP16 as a non-canonical therapeutic target of the PARP1 inhibitor talazoparib, which synergizes with the WEE1 inhibitor adavosertib to enhance its efficacy. The dual targeting of PARP1 and PARP16 may explain the greater efficacy of talazoparib in some cancers.

中文翻译：

---

两只鸟，一块石头：PARP抑制剂他拉唑帕尼的非经典治疗效果

在本期细胞化学生物学中，Palve 等人。(2022) 将 PARP16 确定为 PARP1 抑制剂 talazoparib 的非规范治疗靶点，它与 WEE1 抑制剂 adavosertib 协同作用以增强其疗效。PARP1 和 PARP16 的双重靶向可能解释了他唑帕尼在某些癌症中的更大疗效。